PT  - JOURNAL ARTICLE
AU  - Dev Katarey
AU  - Sumita Verma
TI  - Drug-induced liver injury
AID  - 10.7861/clinmedicine.16-6-s104
DP  - 2016 Dec 01
TA  - Clinical Medicine
PG  - s104--s109
VI  - 16
IP  - Suppl 6
4099  - http://www.rcpjournals.org/content/16/Suppl_6/s104.short
4100  - http://www.rcpjournals.org/content/16/Suppl_6/s104.full
SO  - Clin Med2016 Dec 01; 16
AB  - Drug-induced liver injury (DILI) remains the most common cause of acute liver failure (ALF) in the western world. Excluding paracetamol overdose, nearly all DILI encountered in the clinical setting is idiosyncratic in nature because affected individuals represent only a small proportion of those treated with such drugs. In many cases, the mechanism for idiosyncrasy is immune-mediation and is often identified by genetic risk determined by human leukocyte antigen variants. In the absence of diagnostic tests and/or biomarkers, the diagnosis of DILI requires a high index of suspicion after diligently excluding other causes of abnormal liver tests. Antibiotics are the class of drugs most frequently associated with idiosyncratic DILI, although recent studies indicate that herbal and dietary supplements are an increasingly recognised cause. It is imperative that upon development of DILI the culprit drug be discontinued, especially in the presence of elevated transaminases (aspartate aminotransferase/alanine aminotransferase ratio ≥5 times the upper limit of normal) and/or jaundice. Risk factors for the development ALF include hepatocellular DILI and female gender, the treatment being supportive with some benefit of N-acetylcysteine in the early stages. In view of the poor transplant-free survival in idiosyncratic DILI, early consideration for liver transplant is mandatory.